Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-gene Edited Anti-CD7 CAR T Cells for T Cell Malignancies
NCT04934774Phase 1Unknown
- Sponsor
- iCell Gene Therapeutics
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD7 CAR in t-cell acute lymphoblastic leukemia (T-ALL), T-cell acute lymphoblastic lymphoma (T-LBL) and T-cell non-Hodgkin lymphoma, sponsored by iCell Gene Therapeutics. Primary endpoints: Dose limiting toxicity at 28 days, Type of dose-limiting toxicity at 28 days and 1 more. Status: unknown.
02
Drugs
CD7 CAR
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell acute lymphoblastic lymphoma (T-LBL)T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04934774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934774.